Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Novel germline GATA1s-generating variant associates with somatic STAG2 variants in hypoplastic myelodysplastic neoplasm.

British journal of haematology·2026
Same author

A Rare Pedunculated Lobular Capillary Hemangioma of the Conjunctiva.

Ophthalmic plastic and reconstructive surgery·2026
Same author

Chlorhexidine antiseptic is a harmful protection due to keratitis and blindness potential.

The ocular surface·2026
Same author

Cell-type specific effects of SARS-CoV-2 P252L mutation on nirmatrelvir sensitivity.

Antiviral research·2026
Same author

Economic burden of pulmonary arterial hypertension in Switzerland.

PloS one·2026
Same author

Intravitreal Bevacizumab plus Methotrexate for iris and ciliary body metastasis from lung cancer.

American journal of ophthalmology case reports·2026

Related Experiment Video

Updated: Jan 11, 2026

Formulating and Characterizing Lipid Nanoparticles for Gene Delivery using a Microfluidic Mixing Platform
09:41

Formulating and Characterizing Lipid Nanoparticles for Gene Delivery using a Microfluidic Mixing Platform

Published on: February 25, 2021

24.9K

Novel Wide-Spectrum Virucidal Lipid Nanoparticles.

Yugo Araújo Martins1,2,3, Louise Bondeelle1, Arnaud Charles-Antoine Zwygart1

  • 1Department of Microbiology and Molecular Medicine, Faculty of Medicine, University of Geneva, Geneva, 1211, Switzerland.

Small (Weinheim an Der Bergstrasse, Germany)
|November 14, 2025
PubMed
Summary
This summary is machine-generated.

POSTAN is a novel lipid nanoparticle with broad-spectrum antiviral activity against multiple viruses, including SARS-CoV-2 and RSV. This biocompatible agent demonstrates safety and efficacy for respiratory infections.

Keywords:
COVID‐19coronavirusnanocarrierspulmonary deliveryrespiratory infection

More Related Videos

Testing the In Vitro and In Vivo Efficiency of mRNA-Lipid Nanoparticles Formulated by Microfluidic Mixing
08:55

Testing the In Vitro and In Vivo Efficiency of mRNA-Lipid Nanoparticles Formulated by Microfluidic Mixing

Published on: January 20, 2023

13.7K
Production of siRNA-Loaded Lipid Nanoparticles using a Microfluidic Device
06:02

Production of siRNA-Loaded Lipid Nanoparticles using a Microfluidic Device

Published on: March 22, 2022

10.3K

Related Experiment Videos

Last Updated: Jan 11, 2026

Formulating and Characterizing Lipid Nanoparticles for Gene Delivery using a Microfluidic Mixing Platform
09:41

Formulating and Characterizing Lipid Nanoparticles for Gene Delivery using a Microfluidic Mixing Platform

Published on: February 25, 2021

24.9K
Testing the In Vitro and In Vivo Efficiency of mRNA-Lipid Nanoparticles Formulated by Microfluidic Mixing
08:55

Testing the In Vitro and In Vivo Efficiency of mRNA-Lipid Nanoparticles Formulated by Microfluidic Mixing

Published on: January 20, 2023

13.7K
Production of siRNA-Loaded Lipid Nanoparticles using a Microfluidic Device
06:02

Production of siRNA-Loaded Lipid Nanoparticles using a Microfluidic Device

Published on: March 22, 2022

10.3K

Area of Science:

  • Biotechnology
  • Nanomedicine
  • Virology

Background:

  • Viral infections pose a global health threat, necessitating advanced antiviral therapies.
  • Existing treatments like virustatic and virucidal agents have limitations such as reversible mechanisms or toxicity.
  • There is a critical need for novel, safe, and broad-spectrum antiviral strategies.

Purpose of the Study:

  • To introduce POSTAN, a new biocompatible virucidal lipid nanoparticle designed for direct antiviral action.
  • To evaluate POSTAN's physicochemical properties, toxicity, safety, and broad-spectrum virucidal efficacy.
  • To assess POSTAN's therapeutic potential against respiratory viruses like SARS-CoV-2 and RSV.

Main Methods:

  • POSTAN was engineered using polyoxyethylene sorbitan oleate (PO) and sodium taurodeoxycholate (ST).
  • Physicochemical properties for pulmonary delivery were assessed.
  • Cytotoxicity was evaluated in Vero cells and human airway epithelial (HAE) cultures.
  • In vivo safety was tested in neonatal mice.
  • Virucidal activity was tested against HSV, RSV, Zika virus, CHIKV, and SARS-CoV-2.
  • Efficacy was evaluated in HAE cultures and a neonatal RSV mouse model.

Main Results:

  • POSTAN exhibited optimal properties for pulmonary delivery and showed minimal to no toxicity in cell cultures and a favorable safety profile in mice.
  • POSTAN demonstrated broad-spectrum virucidal activity against multiple viruses by disrupting viral envelopes.
  • In HAE cultures, POSTAN significantly reduced SARS-CoV-2 titers.
  • In a mouse model, POSTAN treatment reduced RSV lung viral titers and mitigated lung pathology.

Conclusions:

  • POSTAN is a safe and effective broad-spectrum antiviral agent.
  • POSTAN shows promise as a therapeutic platform for respiratory viral infections.
  • The nanoparticle's mechanism involves disrupting viral envelopes, offering a novel approach to antiviral therapy.